CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

CAR T-Cell Therapy Side Effects for Blood Cancers

GRACE

A. Goodman

CAR NK Cells: Next Generation Cell Therapies for Cancer

University of Colorado Cancer Center

K. Rezvani

The Improbable History of CAR T-Cells

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

C. June

Interventional Delivery of CAR-T Therapy

Michael Soulen

Bispecific vs. Combination Therapy - PRO Combination Therapy

ImmunoTherapy Bridge 2023

A. Patnaik

CAR T-Cell Failure: Mechanisms and Salvage Options

Beth Israel Deaconess Medical Center

J. Arnason

Bispecific vs. Combination Therapy - PRO Bispecific

ImmunoTherapy Bridge 2023

J. Gulley

Treatment of Symptomatic Brain Metastases in Melanoma: Combination o…

Melanoma Bridge 2023

H. Tawbi

Innovating Immunotherapy for Pancreatic Cancer

ImmunoTherapy Bridge 2023

G. Lesinski

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Total Health

K. Komanduri

CAR-T 101: Overview of CAR-T Therapy and Management of Toxicities

UNC Lineberger Comprehensive Cancer Center

M. Mcelfresh

New and Evolving Clinical Trials: Embolotherapy

SIR 2022 Coverage

M. Soulen

Novel Insights Into the Mechanisms of Radiation-Induced Anti-Tumor I…

ImmunoTherapy Bridge 2023

S. Demaria

IDWeek 2023 Insights: Managing Infectious Complications and Infectio…

Insights from IDWeek 2023

T. Patel

Implementing Cell Therapy in Community Practice: The Lancaster Gener…

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

N. Buescher

Engineered T-Cells

Melanoma Bridge 2023

O. Michielin

Immunotherapy for HCC: Current Status & Future Perspectives

ImmunoTherapy Bridge 2023

P. Federico